Patrick Donnelly

EXACT Sciences Corporation (NASDAQ: EXAS) shares have risen over 50 percent year-to-date, and Goldman Sachs sees further upside ahead.   The Analyst Patrick Donnelly maintained a Buy rating on Exact Sciences shares with a $120 price target. The Thesis Goldman previously ...

Shares of EXACT Sciences Corporation (NASDAQ: EXAS), which markets the non-invasive colon cancer screener Cologuard, enjoy a premium valuation and hold further upside potential, according to Goldman Sachs. The Analyst Analyst Patrick Donnelly upgraded Exact Sciences from Neutral To Buy and...

Goldman Sachs has a pair trade in the life sciences tools and diagnostics space ahead of third-quarter earnings season.  The Analyst Analyst Patrick Donnelly maintained a Buy rating on Agilent Technologies Inc (NYSE: A) and increased the price target from $77 to $82. The analyst...

Shares of the molecular diagnostics name Myriad Genetics (NYSE: MYGN) are worth less than what the Street is paying, according to Goldman Sachs.  The Analyst Goldman Sachs analyst Patrick Donnelly initiated coverage of Myriad Genetics with a Sell and $32 price target, implying a 22-...

Small market caps, attractive growth prospects and idiosyncratic product cycles among diagnostics companies can lead to valuation volatility while also creating attractive M&A opportunities. The Analyst Goldman Sachs analyst Patrick Donnelly initiated coverage on the diagnostics sector with a...